The Australian Pesticides and Veterinary Medicines Authority (APVMA) is considering an application for approval of the new active constituent TASIPIMIDINE SULFATE, and registration of the product Tessie 0.3 mg/mL Oral Solution for Dogs (containing the new active constituent, TASIPIMIDINE SULFATE) for the short-term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure.
We invite relevant written comment from 10 February to 10 March 2026 on whether approval of the active constituent and registration of the product should be granted.
The APVMA is able to consider comments relating to the legislative grounds, including:
- chemistry and manufacture
- occupational health and safety
- public health
- environmental safety
- efficacy and target animal safety.
For more information see page 14 to 28, in the APVMA Gazette No 3, Tuesday 10 February 2026.
Please send your written submission by email or post to:
Case Management
Australian Pesticides and Veterinary Medicines Authority
GPO Box 574
Canberra ACT 2601, Australia
Email: casemanagement@apvma.gov.au